121
Participants
Start Date
September 2, 2020
Primary Completion Date
October 30, 2022
Study Completion Date
November 2, 2022
Therapy
Standardized non-directive therapy performed by therapist team.
Midomafetamine
Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
Placebo
Administration of placebo with therapy during three experimental sessions
New York University, New York
Nautilus Psychiatric Services, New York
Zen Therapeutic Solutions, LLC, Mt. Pleasant
Ray Worthy Psychiatry LLC, New Orleans
Aguazul Bluewater, Inc., Boulder
Wholeness Center, Fort Collins
New School Research, Los Angeles
San Francisco Insight and Integration Center, San Francisco
UCSF, San Francisco
University of Connecticut, Farmington
Trauma Research Foundation, Boston
University of Wisconsin - Madison, Madison
Assaf Harofeh Research Fund, Beer Yaaqov
Sheba Fund for Health Services and Research, Tel Litwinsky
Lead Sponsor
Lykos Therapeutics
INDUSTRY